Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 21, 2024 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Deeper Insights, Including Fluid Biomarker Data for Sabirnetug (ACU193), During Emerging Science Session at the American Academy of Neurology Annual Meeting

- Company on track to initiate Phase 2 trial evaluating sabirnetug in first half of 2024 CHARLOTTESVILLE, Va., March 21, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a...
March 19, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2023 Financial Results on March 26, 2024

CHARLOTTESVILLE, Va., March 19, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel...
March 12, 2024 16:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel 2024 CNS Days

CHARLOTTESVILLE, Va., March 12, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
March 08, 2024 08:50 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

- Cerebrospinal fluid (CSF) biomarker results are highly supportive of sabirnetug’s downstream pharmacological effects in the brain in early AD - Poster presentation showcases method used to develop...
February 21, 2024 08:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer’s at the AD/PD™ 2024 Annual Meeting

- Oral presentation to explore drug effect of sabirnetug (ACU193) on key cerebrospinal fluid biomarkers in early AD - Poster presentation to showcase method used to develop a first-of-its-kind...
February 01, 2024 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Appoints Dr. James Doherty as President and Chief Development Officer

CHARLOTTESVILLE, Va., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic...
January 04, 2024 16:15 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Acumen Pharmaceuticals to present at the JPMorgan Healthcare Conference.
November 13, 2023 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Highlights

Initiation of a Phase 2 study, ALTITUDE-AD, to investigate ACU193 for the treatment of early Alzheimer’s disease expected in the first half of 2024, following positive FDA interaction in October 2023 ...
November 13, 2023 07:00 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals Secures $50.0 Million Credit Facility with K2 HealthVentures

Provides additional capital to support development of a subcutaneous formulation of ACU193 and general corporate purposes$30 million drawn down at loan closing CHARLOTTESVILLE, Va., Nov. 13, 2023 ...
November 07, 2023 16:01 ET | Source: Acumen Pharmaceuticals, Inc.

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

CHARLOTTESVILLE, VA. and INDIANAPOLIS, IN., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic...